Journal article
Idarucizumab for Dabigatran Reversal — Full Cohort Analysis
Abstract
BACKGROUND: Idarucizumab, a monoclonal antibody fragment, was developed to reverse the anticoagulant effect of dabigatran.
METHODS: We performed a multicenter, prospective, open-label study to determine whether 5 g of intravenous idarucizumab would be able to reverse the anticoagulant effect of dabigatran in patients who had uncontrolled bleeding (group A) or were about to undergo an urgent procedure (group B). The primary end point was the …
Authors
Pollack CV; Reilly PA; van Ryn J; Eikelboom JW; Glund S; Bernstein RA; Dubiel R; Huisman MV; Hylek EM; Kam C-W
Journal
The New England Journal of Medicine, Vol. 377, No. 5, pp. 431–441
Publisher
Massachusetts Medical Society
Publication Date
August 3, 2017
DOI
10.1056/nejmoa1707278
ISSN
0028-4793